Assessing the suitability of long non-coding RNAs as therapeutic targets and biomarkers in SARS-CoV-2 infection.
Front Mol Biosci
; 9: 975322, 2022.
Article
in English
| MEDLINE | ID: covidwho-2022799
ABSTRACT
Long non-coding RNAs (lncRNAs) are RNA transcripts that are over 200 nucleotides and rarely encode proteins or peptides. They regulate gene expression and protein activities and are heavily involved in many cellular processes such as cytokine secretion in respond to viral infection. In severe COVID-19 cases, hyperactivation of the immune system may cause an abnormally sharp increase in pro-inflammatory cytokines, known as cytokine release syndrome (CRS), which leads to severe tissue damage or even organ failure, raising COVID-19 mortality rate. In this review, we assessed the correlation between lncRNAs expression and cytokine release syndrome by comparing lncRNA profiles between COVID-19 patients and health controls, as well as between severe and non-severe cases. We also discussed the role of lncRNAs in CRS contributors and showed that the lncRNA profiles display consistency with patients' clinic symptoms, thus suggesting the potential of lncRNAs as drug targets or biomarkers in COVID-19 treatment.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Observational study
Topics:
Long Covid
Language:
English
Journal:
Front Mol Biosci
Year:
2022
Document Type:
Article
Affiliation country:
Fmolb.2022.975322
Similar
MEDLINE
...
LILACS
LIS